Vickers Vantage Corporat... Quote - VCKA

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

9.01

Bid

10.20

Offer

10.38

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

1.405B

Previous Close

9.01

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

155,943,000

Dividend Yield

PE Ratio

-0.70

Earnings Per Share (EPS)

-0.73

Revenue

46.74M

Net Profit

-114.33M

Vickers Vantage Corp I is a blank check company. Vickers Vantage Corp I is a blank check company.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.scilexholding.com

Headquarters

Wilmington, Delaware, USA

Founded

Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on F

SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is...

Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development...

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa

PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for...

Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topica

30 million lives now covered by one of the largest national PBMsContinue to work with this PBM to access an additional 20 million livesThe team continues to work with the national PBM’s and health...

Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.

Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain...

Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE...

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As...

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes

SAN DIEGO and PALO ALTO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc...

Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system...

Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination betwee

PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PDYNPalladyne AI Corporation	US$ 4.59 (129.50%)	83.07M
QMCOQuantum Corporation	US$ 9.11 (126.62%)	39.48M
NANano Labs Ltd	US$ 8.26 (89.02%)	2.03M
XCURExicure Inc	US$ 18.60 (71.27%)	4.59M
SKKSKK Holdings Limited	US$ 1.75 (59.09%)	107.47M
AMIXAutonomix Medical Inc	US$ 6.21 (-54.07%)	946.09k
CETXCemtrex Inc	US$ 0.1146 (-41.74%)	24.39M
MSWMing Shing Group Holdings Ltd	5.90 (-35.52%)	417.08k
RMSGReal Messenger Corporation	US$ 3.09 (-26.25%)	313.51k
ENSCEnsysce Biosciences Inc	US$ 0.4414 (-25.49%)	4M
ELABElevai Labs Inc	US$ 0.0201 (-0.50%)	425.38M
NVDANVIDIA Corporation	US$ 141.95 (-3.22%)	236.51M
SMCISuper Micro Computer Inc	US$ 33.15 (11.62%)	159.61M
VRPXVirpax Pharmaceuticals Inc	US$ 0.5501 (-6.72%)	159.39M
SOUNSoundHound AI Inc	US$ 8.24 (18.05%)	107.91M